Currently Viewing:
Newsroom
Currently Reading
Researchers Consider Existence of Pulmonary Vascular Phenotype Among COPD Patients
October 27, 2018 – Alison Rodriguez
Study Investigates Impact of Migraine on Clinical Presentation of Insomnia
October 26, 2018 – Alison Rodriguez
ACO Engagement With Urologists Can Reduce Overtreatment of Prostate Cancer
October 21, 2018 – Laura Joszt
Combination of Medicine, Exercise Training, Behavior Modification Improves COPD Symptoms
October 19, 2018 – Allison Inserro
Long-Term Benzodiazepine Use in COPD, PTSD May Increase Suicide Risk, Study Says
October 19, 2018 – Alison Rodriguez
Low-Dose Theophylline Not Effective at Reducing COPD Exacerbations, Study Finds
October 16, 2018 – Allison Inserro
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14, 2018 – Laura Joszt
FDA Approves Arikayce to Treat Certain Patients With Rare Lung Disease
October 11, 2018 – Alison Rodriguez
Anti–PD-1 Immunotherapy Helps With Coexisting Chronic Inflammation From COPD, NSCLC
October 10, 2018 – David Bai, PharmD

Researchers Consider Existence of Pulmonary Vascular Phenotype Among COPD Patients

Alison Rodriguez
Researchers reviewed the most updated concepts of the pulmonary vascular changes in chronic obstructive pulmonary disease (COPD) and concluded that certain subgroups of COPD patients with pulmonary vascular phenotypes may profit from targeted pulmonary arterial hypertension therapy.
Chronic obstructive pulmonary disease (COPD) often affects pulmonary vessels and mild pulmonary hypertension (PH) is a common feature of COPD. Researchers reviewed the most updated concepts of the pulmonary vascular changes in COPD and concluded that certain subgroups of COPD patients with pulmonary vascular phenotypes may profit from targeted pulmonary arterial hypertension (PAH) therapy. The findings were published in the American Journal of Respiratory and Critical Care Medicine.

The authors noted that certain mechanisms alone or in combination can alter pulmonary circulation of patients with COPD, including tobacco smoking, endothelial dysfunction, structural and functional lung abnormalities, inflammation, and genetic background. The authors assessed the impact of these mechanisms, as well as defining and classifying pulmonary vascular disease in COPD.

The diagnostic classification of PH proposed 5 distinct groups:
Group 1: PAH
Group 2: PH caused by left heart disease
Group 3: PH caused by lung diseases and/or hypoxia
Group 4: Chronic thromboembolic PH
Group 5: PH with unclear and/or multifactorial mechanisms


“The presence of mild airflow limitation (FEV1, >60%), mild or missing lung parenchymal abnormalities on high resolution chest computed tomography, and a primary cardiovascular limitation found during cardiopulmonary exercise testing favor classification into group 1 (PAH), whereas more severe airflow limitation (FEV1, <60%), significant lung parenchymal abnormalities on high resolution chest computed tomography, and a ventilatory limitation during exercise testing favor group 3 PH,” explained the authors.

The authors also considered whether a pulmonary vascular phenotype COPD exists, finding that the there is a tentative working definition of the pulmonary vascular phenotype of COPD based on the presence of severe PH with moderate airflow limitation and no hypercapnia, very low diffusing capacity of the lungs for carbon monoxide (DLco), and circulatory exercise limitation and/or progressive right heart failure, according to the report.

“The pulmonary circulation is often abnormal in patients with COPD. Although their [pulmonary arterial pressure] elevation is generally mild, it is associated with a higher frequency of severe exacerbations and hospitalizations as well as poor survival,” concluded the authors. “However, there is a subgroup of patients with COPD characterized by moderate airflow limitation, severe precapillary PH, relatively low PaCO2 levels, strongly impaired DLco, progressive right heart failure, and very poor survival.”

The report called for more clinical attention and directed research regarding pulmonary circulation and COPD in the future in order to address the gaps in knowledge and data.

Reference

Kovacs G, Agusti A, Barberà JA, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? Am J Respir Crit. 2018;198(8):1000-1011. doi: 10.1164/rccm.201801-0095PP.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up